Fermenta Biotech share price
NSE: FERMENTABSE: 506414Pharmaceuticals & BiotechnologySmall Cap
Fermenta Biotech Limited · Face value ₹5 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Oct 1977 on BSE, Apr 2026 on NSE
Last close ₹439.10down ₹3.65 (0.82%)BSE ₹439.75
Share price at the NSE close on 29 Oct 2026. Previous close ₹442.75.
29 Oct: open ₹446.45, high ₹448.30, low ₹428.00
52-week range of BSE trades to 29 Oct 2026
₹256.40Low, 5 Dec 2025₹582.95High, 6 Oct 2026
- Next results date: the board meets on 5 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹1,292 Cr1,508th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Earlier quarters restated in the year
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 3.18
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.85%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 13.5%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.27
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 57,77651.0% delivered
Results
Consolidated; ₹ crore.Fermenta Biotech quarterly results
- Revenue growth, 12 monthsRevenue growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- −3.2%
- Net profit growth, 12 monthsNet profit growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- –
Quarter to Jun 2026, against the quarter before
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹122 Crup 0.20%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent. Net profit in the glossary
- ₹9.53 Crdown 48.76%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 7.8%
Revenue by quarter
Peak revenue ₹156 Cr, quarter to Dec 2024; lowest ₹95 Cr, quarter to Sep 2024
Net profit by quarter, a loss in red
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 95 | 156 | 140 | 136 | 130 | 137 | 122 | 122 |
| Net profit | 11 | 38 | 33 | 22 | 18 | 12 | 19 | 10 |
| Net margin | 11.7% | 24.2% | 23.8% | 15.9% | 13.8% | 8.8% | 15.3% | 7.8% |
Consolidated. The last eight quarters. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Year to Mar 2026, against the year before
- RevenueRevenue. The pill is the change in revenue against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹525 Crup 11.92%
- Net profitNet profit. The pill is the change in net profit against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹70 Crdown 8.05%
- Net margin
- 13.4%
Revenue by year
Peak revenue ₹525 Cr, year to Mar 2026; lowest ₹167 Cr, year to Mar 2017
Net profit by year, a loss in red
- Net profit
- Loss
A loss in 2 of the 10 years shown
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 167 | 303 | 405 | 293 | 377 | 399 | 350 | 336 | 469 | 525 |
| Net profit | 10 | 48 | 117 | 60 | 43 | 15 | −54 | −24 | 76 | 70 |
| Net margin | 6.1% | 15.9% | 29.0% | 20.3% | 11.3% | 3.8% | −15.3% | −7.2% | 16.3% | 13.4% |
Consolidated. Years to March. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Business segments
Share of revenue, year to Mar 2026, consolidated.Segment revenue and profit
- Bulk drugs/chemicalsBulk drugs/chemicals, share of revenue. The segment's revenue as a percentage of the revenue of all the company's reported business segments together, leaving out eliminations between them and unallocated items.₹515 Crup 28.52%98.2%
- PropertyProperty, share of revenue. The segment's revenue as a percentage of the revenue of all the company's reported business segments together, leaving out eliminations between them and unallocated items.₹10 Crdown 82.51%1.8%
The pill is the change in revenue on the year before; the share is of all the businesses together.
Valuation
Today, against the company's own history. Not shown, P/E: a results filing in the last twelve months restated the quarters before it inside its year to date, so the four quarters as the company reported them do not add to a twelve-month profit; the ratio returns once the trailing year no longer holds a quarter from before the restatement.Fermenta Biotech PE ratio and valuation
Price to book
At or below today's level on 77% of 1,836 trading days since Nov 2018.
LowestHighest
Its median2.49Industry median2.97
Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.
At or below today's level on 100% of 2,382 trading days over the last 10 years.
LowestHighest
Its median0.00%Industry median0.48%
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | +17.8% | −6.3% | +24.4% | 1.2% |
| 3 years | +44.3% | – | – | 0.4% |
| 5 years | +5.2% | +10.7% | −5.2% | 0.2% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth and the change in P/E are left empty where earnings per share at either end of the window was a loss or is not on record. Earnings growth over 3 and 5 years is on profit divided by shares in issue at both ends: the earnings per share stated for one end does not match that year's profit and share count.
Mutual fund holdings
2 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 2 of the 2 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future.
- AddedAdded. Funds that held more shares than at the end of the month before.
- 2
| Fund | |||
|---|---|---|---|
 Motilal Oswal BSE Healthcare ETFMotilal Oswal Mutual Fund | 262 | 0.03% | ₹0.01 Cr |
 Bandhan BSE Healthcare Index FundBandhan Mutual Fund | 124 | 0.03% | ₹68,000 |
Portfolios disclosed for Sep 2026. Weight is the holding as a share of the fund's assets.
Promoter and insider buying and selling
Trades made since 30 Oct 2025.Fermenta Biotech insider trading
Bought on the marketBought on the market. The value each filer stated for its purchases on the exchange, added up; gifts, transfers and pledges are not counted. A purchase filed with no value is counted under the sum, not in it. Sold on the marketSold on the market. The value each filer stated for its sales on the exchange, added up; gifts, transfers and pledges are not counted. A sale filed with no value is counted under the sum, not in it.
- Promoters and promoter group0 purchases, 1 saleNo purchase₹55 CrNetNet. The value bought on the market less the value sold, over the trades whose filers stated a value.−₹55 Cr
- Directors and key managers0 purchases, 1 saleNo purchase₹2.20 CrNet−₹2.20 Cr
- Others0 purchases, 3 salesNo purchase₹0.20 CrNet−₹0.20 Cr
Bought and sold count trades on the market only. A pledge is shares given to a lender as security for a loan; a lender invokes it by selling them.
Fermenta Biotech competitors and peers
Pharmaceuticals, 215 listed companies, priced on 29 Oct 2026. The table lists the 8 companies closest to Fermenta Biotech in market cap.Healthcare companies
Fermenta Biotech is not on the chart: it has no P/E or return on equity today
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Jagsonpal PharmaceuticalsJAGSNPHARM | 1,466 | 32.23 | 6.09 | +6.4% | −26.6% | 18.3% | 21.7% | 1.80% |
 Amrutanjan Health CareAMRUTANJAN | 1,426 | 26.42 | 3.85 | +10.7% | −1.0% | 15.5% | 18.0% | 0.99% |
 Anlon HealthcareAHCL | 1,335 | 48.03 | 5.19 | – | – | 12.7% | 16.6% | 0.00% |
 Bharat ParenteralsBPLPHARMA | 1,318 | 1,059.70 | 3.97 | +10.6% | – | 0.4% | −0.3% | 0.05% |
 KopranKOPRAN | 1,218 | 48.75 | 2.30 | +12.0% | −28.4% | 4.8% | 6.2% | 1.19% |
 Bafna PharmaceuticalsBAFNAPH | 1,081 | 138.85 | 11.24 | −3.1% | −5.8% | 8.6% | 4.0% | 0.00% |
 Bajaj HealthcareBAJAJHCARE | 1,053 | 51.09 | 1.89 | +14.2% | −55.0% | 4.0% | 10.2% | 0.48% |
 Remus PharmaceuticalsREMUS | 1,030 | 27.84 | 2.93 | +37.6% | – | 12.2% | 13.1% | 0.11% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Dividends
Per share, by the year it was paid for, and the latest payments.Fermenta Biotech dividend history
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up. Dividend per share in the glossaryHighest ₹3.75 a share, year to Mar 2026.
| Ex-date | Type | Per share |
|---|---|---|
| 5 Aug 2026 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. Final dividend in the glossary | ₹3.75 |
Latest payments, as declared, by ex-date.
Latest announcements
Routine notices left out.Fermenta Biotech announcements
Oct 2026
12 Oct · Analysts
1 Oct · Analysts
Sep 2026
29 Sep · Analysts
24 Sep · Analysts
Fermenta Biotech share price by year
Each calendar year to 2025.Fermenta Biotech share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025BSE close | 348.00 | −4.4% | 422.90 | 225.35 |
| 2024BSE close | 363.95 | +125.2% | 418.65 | 146.40 |
| 2023BSE close | 161.60 | −7.0% | 189.25 | 106.95 |
| 2022BSE close | 173.70 | −40.1% | 309.90 | 173.70 |
| 2021BSE close | 290.15 | −8.6% | 360.90 | 250.30 |
| 2020BSE close | 317.50 | – | 427.75 | 157.60 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. 2020 is from its first session, 13 Feb 2020.
Recent sessions
The 9 trading days to 28 Oct 2026, as traded on NSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 28 Oct 2026 | 442.10 | 461.00 | 441.10 | 442.75 | 448.26 | 26,368 | 46.9% |
| 27 Oct 2026 | 442.65 | 464.20 | 442.25 | 447.65 | 453.57 | 33,114 | 34.4% |
| 26 Oct 2026 | 450.60 | 467.40 | 441.05 | 447.05 | 453.98 | 83,538 | 25.8% |
| 23 Oct 2026 | 462.00 | 462.70 | 435.00 | 450.60 | 448.57 | 1,01,165 | 40.9% |
| 22 Oct 2026 | 468.00 | 468.05 | 452.70 | 458.35 | 459.59 | 45,998 | 47.4% |
| 21 Oct 2026 | 462.30 | 477.15 | 451.60 | 465.00 | 463.54 | 1,13,861 | 43.9% |
| 19 Oct 2026 | 485.00 | 490.20 | 456.40 | 460.50 | 469.32 | 84,469 | 47.2% |
| 16 Oct 2026 | 488.00 | 494.55 | 482.00 | 486.00 | 487.40 | 52,737 | 42.8% |
| 15 Oct 2026 | 500.15 | 507.50 | 485.05 | 486.50 | 490.60 | 72,765 | 59.1% |
Prices in ₹ per share as traded, not adjusted.
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Buyback history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 13 Feb 2020 | Price move | – | Between two trading sessions the price fell 47% or more, or rose 90% or more. No corporate action is on record. Earlier prices are not shown. |
| 8 Aug 2018 | Price move | – | Between two trading sessions the price fell 47% or more, or rose 90% or more. No corporate action is on record. Earlier prices are not shown. |
Where an event has no factor that can be worked out, the chart leaves out the closes before it.
Company details
- NSE symbol
- FERMENTA
- BSE code
- 506414
- ISIN
- INE225B01021
- Industry
- Pharmaceuticals & Biotechnology
- Website
- www.fermentabiotech.com
- CIN
- L99999MH1951PLC008485
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 1951
- Registered office
- A -1501, Thane One, DIL Complex, Ghodbunder Road, Majiwade, Thane (West), 400610, Maharashtra
- Share registrar
- MUFG Intime India Pvt. Ltd
- Keeps the register of shareholders and handles transfers and dividend payments